Head-To-Head Review: Revelation Biosciences (NASDAQ:REVB) versus Bristol-Myers Squibb (NYSE:BMY)

Revelation Biosciences (NASDAQ:REVB) and Bristol-Myers Squibb (NYSE:BMY) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends and profitability.

Volatility & Risk

Revelation Biosciences has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.

Insider and Institutional Ownership

12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 76.4% of Bristol-Myers Squibb shares are held by institutional investors. 0.2% of Revelation Biosciences shares are held by company insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Revelation Biosciences and Bristol-Myers Squibb’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Revelation Biosciences	N/A	-152.41%	-74.43%
Bristol-Myers Squibb	-14.06%	12.51%	3.03%

Analyst Ratings

This is a breakdown of recent ratings for Revelation Biosciences and Bristol-Myers Squibb, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revelation Biosciences	0	0	0	0	N/A
Bristol-Myers Squibb	2	13	2	0	2.00

Bristol-Myers Squibb has a consensus price target of $54.67, indicating a potential upside of 11.07%. Given Bristol-Myers Squibb’s higher probable upside, analysts plainly believe Bristol-Myers Squibb is more favorable than Revelation Biosciences.

Valuation and Earnings

This table compares Revelation Biosciences and Bristol-Myers Squibb’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revelation Biosciences	N/A	N/A	-$120,000.00	($30.91)	-0.03
Bristol-Myers Squibb	$45.01 billion	2.22	$8.03 billion	($3.10)	-15.90

Bristol-Myers Squibb has higher revenue and earnings than Revelation Biosciences. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Bristol-Myers Squibb beats Revelation Biosciences on 9 of the 12 factors compared between the two stocks.

About Revelation Biosciences

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.